• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,808.48 544.15
( 0.71%)
Global Indices
Nasdaq
51,705.57 482.31
(0.94%)
Dow Jones
7,575.20 122.74
(1.65%)
Hang Seng
69,393.70 76.20
(0.11%)
Nikkei 225
10,435.69 -36.03
(-0.34%)
Forex
USD-INR
94.92 -0.57
(-0.60%)
EUR-INR
109.83 -0.42
(-0.38%)
GBP-INR
127.25 -0.49
(-0.38%)
JPY-INR
0.59 0.00
(-0.48%)

EQUITY - MARKET SCREENER

ERIS Lifesciences Ltd
Industry :  Pharmaceuticals - Indian - Formulations
BSE Code
ISIN Demat
Book Value()
540596
INE406M01024
230.6075957
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ERIS
75.59
19200.58
EPS(TTM)
Face Value()
Div & Yield %
18.33
1
0.52
 

genpharmasec limited
Timken India consolidated net profit declines 16.81% in the March 2026 quarter
May 19,2026
Net profit of Timken India declined 16.81% to Rs 158.31 crore in the quarter ended March 2026 as against Rs 190.31 crore during the previous quarter ended March 2025. Sales rose 14.54% to Rs 1089.83 crore in the quarter ended March 2026 as against Rs 951.46 crore during the previous quarter ended March 2025.

For the full year,net profit declined 10.23% to Rs 414.89 crore in the year ended March 2026 as against Rs 462.19 crore during the previous year ended March 2025. Sales rose 8.78% to Rs 3478.03 crore in the year ended March 2026 as against Rs 3197.20 crore during the previous year ended March 2025.

ParticularsQuarter EndedYear Ended
Mar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var.
Sales1089.83951.46 15 3478.033197.20 9
OPM %22.1822.51 -18.1819.12 -
PBDT241.63227.17 6 658.68657.79 0
PBT212.03206.22 3 552.63572.68 -4
NP158.31190.31 -17 414.89462.19 -10